It's coming
This is a Phase Ib/II Study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of AK119 combined with AK104 in tumor patients.
Solid Tumor, Adult
AK119
AK104
Phase 1
Phase 2
Study Type : | Interventional |
Estimated Enrollment : | 102 participants |
Masking : | None (Open Label) |
Primary Purpose : | Treatment |
Official Title : | A Multicenter, Open-Label, Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of AK119 Combined With AK104 in Patients With Advanced Solid Tumors |
Actual Study Start Date : | December 15, 2022 |
Estimated Primary Completion Date : | March 2024 |
Estimated Study Completion Date : | September 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: AK119+AK104 AK119 and AK104 IV every 2 or every 3 weeks. |
Drug: AK119 Drug: AK104 |
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Recruiting
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin, China, 300060